ASH25 Day 2: Don’t Miss The Highlights

The American Society of Hematology Congress 2025 (ASH25) is officially underway in Orlando, Florida, from December 6 to 9.

It aims to bring together hematology professionals from across the globe.

Throughout the meeting, experts will present new research, clinical breakthroughs, and innovations that are defining the future of hematologic care.

Find the highlights from Day 2

The Lancet Haematology:

”A poster on API-CAT trial post-hoc analyses is being presented at ASH25!

In API-CAT, patients with active cancer who’ve had six months of anticoagulation might benefit from a lower apixaban dose during extended treatment — potentially lower bleeding risk while keeping recurrent VTE risk low.

However, bleeding on extended anticoagulation is still a concern for clinicians.

We already understand the drivers in the first six months for cancer-associated VTE on anticoagulation, but the factors in the extended period remain unknown.

This post-hoc analysis sheds light on these factors!

Don’t miss this poster (#1343) and the opportunity to meet Isabelle Mahé in person today!

And read the full article here.

”

Wolfgang Miesbach:

”iTTP remission ≠ cure.

The vascular injury persists.

TTP as a cardiovascular disease equivalent.

Just finished Dr. Senthil Sukumar‘s ASH25 session on long-term iTTP management.

This completely changed how I think about these patients.

The Numbers Hit Different:

• 28.6% of survivors → major cardiovascular events
• 50% → silent cerebral infarcts (vs 16.6% controls)
• Cardiovascular complications 10–20 years EARLIER
• 80% depression | 35% post traumatic stress disorder
• >60% measurable neurocognitive impairment
• 71% moderate-severe headaches
• 20% can’t work due to complications

The Game Changer: Endothelial Damage That Doesn’t Heal

Patients are not “fine” after remission.

The endothelium stays injured.

Stress cardiac MRI shows reduced perfusion + impaired coronary vasodilation—the heart can’t increase blood flow under stress even when ADAMTS13 normalizes.

The Actionable Part
ADAMTS13 ≤70% = 27.6% stroke rate
ADAMTS13 >70% = ZERO ischemic strokes

As a consequence, treat iTTP as CVD Equivalent

• Comprehensive cardiovascular risk factor optimization (lipids, A1C, smoking, BP, weight, activity)
• Baseline mood + neurocognitive screening for ALL survivors
• Neuropsych testing every 1–2 years
• Multidisciplinary teams (neuro, psych, cardio)

”

Akshat Jain:

”Day 2 ASH2025 American Society of Hematology meeting so far is showing some great insights in basic science of understanding ongocenesis in Hematologic conditions.

1. Clonal Hematopiesis ( CH ) ans red cell aging is accelerated in people with Sickle Cell Disease and its implications run deep especially for people who have or planning on receiving cell and gene therapy.

Risk of CH and marrow stress needs should give us pause and consideration when doing patient selection for Transformative therapies for hemoglobinopathies.

2. Are Regulatory T cells TRegs the answer for brain injury in Sickle cell disease?

3. Cannabis use in outcomes of fetal and maternal health in Sickle Cell pregnancies! very important work.

”

Danielle Hammond:

”Stop by this evening’s ASH25 poster session to see how early therapeutic intervention in high-risk CCUS is being explored in this TiP (Poster 3160).

Hands up to the visionary BTC effort and co-investigators: Lachelle Dawn, Amy DeZern, Sanam Loghavi, Maximilian Stahl, MD Anderson Cancer Center

”

Rudra Narayan Swain:

”As Discussed in Friday symposium – Achieving compressive care in cITP. ASH25

Our study this week in blood research

•Fatigue is highly prevalent in ITP—reported by 77% of untreated persistent/chronic ITP patients.
•Patients had significantly lower FACIT scores vs. controls (146 vs. 155; p<0.001).
•IL-12 levels were markedly elevated in ITP (313.2 vs. 95.5 pg/mL; p<0.001)
•IL-12 showed a consistent negative correlation with all HRQoL domains, including fatigue.
•Independent predictors of higher fatigue burden:
•Female sex
•Disease duration >2 years
•Elevated IL-12 levels
•Findings suggest a potential immunological basis for fatigue in ITP, mediated through Th1 / neuroimmune pathways.
•IL-12 may serve as a biomarker of symptom burden, opening pathways for targeted therapeutic strategies.
•Fatigue remains under-recognized clinically despite being one of the most disabling symptoms for patients.

”

Orlando Palma-Moreno:

”New PVI tool for ITP: a simple score using platelet variability predicts ITP likelihood with clear categories.

Cleaner interpretation equals better diagnosis flow.

”

Sridevi Rajeeve:

”ASH25 Safety data from Phase 1 KTX-1001 (MMSET/NSD2 inhibitor) in heavily pretx RRMM (n=40)

Saad Z. Usmani
– tolerable TEAE with low Tx DC rates (2.5%), reduced H3K36me2 at C2D1 marrow.

Single agent activity esp in t(4;14) look promising for upcoming combinations with carf/mezi.

”

Marc Carrier:

”ATE and VTE worsen symptom burden in cancer

In a population study (n≈59K), ATE ↓ ESAS uptake despite ↑ clinic visits, while VTE ↑ ESAS use.

Both ATE & VTE led to higher odds of worsening pain, anxiety, depression, SOB & wellbeing.

Supports better monitoring plus thromboprophylaxis.

”

Raul Cordoba:

”ASH25: IV iron in hospitalized patients with iron-deficiency anemia and active infection seems to be safe and doesn’t worsen survival.

”

Dan Budwick:

”UW⁩’s Allison Wheeler presents ⁦STAR BiotechPh 1/2 data for VGA039 in von Willebrand Disease with a once monthly subcutaneous dose.

Regulatory bar for VWD is a 50% substantial bleed reduction…in the 8 patients presented, VGA039 showed a 70-100% reduction.

”

More from ASH25 featured in Hemostasis Today.